CD274 and neoplasm: However, analyzing the clinical activity of individual components of 13 phase III anti-PD-(L)1 combination trials (and other relevant trials of individual components) across tumor types, Palmer and colleagues found no evidence of synergy between individual agents, instead concluding that the individual components benefit distinct patient populations, with this strategy offering patients multiple chances of response, highlighting the need for better predictors of anti-PD-(L)1 benefit to guide treatment decisions beyond anti-PD-L1 monotherapy (23).